A clinical trial is a study that investigators conduct in order to determine whether a new treatment is safe and effective in patients. These closely monitored trials are required by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) for the approval of any new drug.

NeoTX is currently conducting a clinical trial that is primarily aimed at determining the safety of NAP in combination with checkpoint inhibitors. Checkpoint inhibitors by themselves are not effective for many patients with advanced or metastatic cancers.

Patients will be treated with a combination of NAP and the checkpoint inhibitor IMFINZI® (durvalumab), developed by AstraZeneca, that has already been approved to treat certain cancers. We believe NAP and IMFINZI® have the potential to work together to help patients who have not responded to previous therapies.
NAP works by binding bacterial components to the tumor surfaces to aid in the recognition of the tumor by the immune system. The drug elicits a natural antibacterial response directed against the tumor.

NeoTX is currently recruiting patients at three locations in Israel:

  • Rambam Medical Center
  • Sheba Medical Center
  • Tel Aviv Sourasky Medical Center

To learn more about the trial, including details about who is eligible and contact information for the trial locations, please talk to your physician or visit clinicaltrials.gov.

NeoTX has designed the Phase 1b clinical trial to determine the maximum tolerated dose (MTD) of NAP in combination with durvalumab, AstraZeneca’s PD-1/PL-L1 checkpoint inhibitor. The trial is currently recruiting patients with previously treated solid tumors that have a high likelihood of 5T4 antigen expression.

Following the dose escalation portion of the study, NeoTX intends to continue into the MTD expansion portion of the study, in which a cohort of 10-15 patients will be treated with the established MTD of NAP in combination with durvalumab. This portion of the trial will also recruit patients with previously treated solid tumors that have a high likelihood of 5T4 antigen expression, with a requirement of measurable disease. This expansion cohort will help assess the biologic activity of the combination and to gain some preliminary insights on its potential antitumor activity.

The goals of the trial are to:
– Evaluate the safety and tolerability of NAP in combination with durvalumab
– Determine a maximum tolerated dose (MTD)
– Establish a recommended Phase 2 dose

For additional study details, please visit clinicaltrials.gov.

A clinical trial is a study that investigators conduct in order to determine whether a new treatment is safe and effective in patients. These closely monitored trials are required by agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) for the approval of any new drug.

NeoTX is currently conducting a clinical trial that is primarily aimed at determining the safety of NAP in combination with checkpoint inhibitors. Checkpoint inhibitors by themselves are not effective for many patients with advanced or metastatic cancers.

Patients will be treated with a combination of NAP and the checkpoint inhibitor IMFINZI® (durvalumab), developed by AstraZeneca, that has already been approved to treat certain cancers. We believe NAP and IMFINZI® have the potential to work together to help patients who have not responded to previous therapies.
NAP works by binding bacterial components to the tumor surfaces to aid in the recognition of the tumor by the immune system. The drug elicits a natural antibacterial response directed against the tumor.

NeoTX is currently recruiting patients at three locations in Israel:

  • Rambam Medical Center
  • Sheba Medical Center
  • Tel Aviv Sourasky Medical Center

To learn more about the trial, including details about who is eligible and contact information for the trial locations, please talk to your physician or visit clinicaltrials.gov.

NeoTX has designed the Phase 1b clinical trial to determine the maximum tolerated dose (MTD) of NAP in combination with durvalumab, AstraZeneca’s PD-1/PL-L1 checkpoint inhibitor. The trial is currently recruiting patients with previously treated solid tumors that have a high likelihood of 5T4 antigen expression.

Following the dose escalation portion of the study, NeoTX intends to continue into the MTD expansion portion of the study, in which a cohort of 10-15 patients will be treated with the established MTD of NAP in combination with durvalumab. This portion of the trial will also recruit patients with previously treated solid tumors that have a high likelihood of 5T4 antigen expression, with a requirement of measurable disease. This expansion cohort will help assess the biologic activity of the combination and to gain some preliminary insights on its potential antitumor activity.

The goals of the trial are to:
– Evaluate the safety and tolerability of NAP in combination with durvalumab
– Determine a maximum tolerated dose (MTD)
– Establish a recommended Phase 2 dose

For additional study details, please visit clinicaltrials.gov.